Prizma will be lapped up by consumer wanting to look after their health . The potential is huge with just a small percentage of consumers buying in each country. With every prizma, comes 2 years of revenue. @Glyco may want to run some numbers on the prizma? Now after that 2 years, some will discontinue, some will sign up again and some will upgrade their model to the g3, g4 model and pass the other one onto another consumer or trade in if company goes down that path.
Also they will also be loaned out with doctors/ specialist to patients, so once having one on loan, some will buy. Hospitals/ insurance companies will also play a role in suggestive selling after a stay in hospital.
Patch will be big revenue earner as well but its not a consumer base product that retail will be selling over the counter, which means the prizma will be available to everyone worldwide, which will make it the company top seller
GMV Price at posting:
8.3¢ Sentiment: None Disclosure: Not Held
